Pfizer (NYSE:PFE) Downgraded by StockNews.com

StockNews.com lowered shares of Pfizer (NYSE:PFE) from a buy rating to a hold rating in a research report sent to investors on Tuesday.

A number of other equities analysts have also commented on the company. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an equal weight rating in a research note on Wednesday, July 31st. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an equal weight rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a neutral rating to an outperform rating and lifted their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a neutral rating in a research report on Wednesday, July 31st. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, September 16th. Nine investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of Moderate Buy and an average price target of $34.54.

Pfizer Stock Up 0.8 %

PFE opened at $28.58 on Tuesday. The stock’s fifty day moving average is $29.17 and its 200-day moving average is $28.31. The company has a market capitalization of $161.95 billion, a PE ratio of -476.33, a P/E/G ratio of 1.25 and a beta of 0.67. Pfizer has a one year low of $25.20 and a one year high of $33.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 earnings per share. On average, equities analysts predict that Pfizer will post 2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several large investors have recently bought and sold shares of PFE. Capital International Ltd. CA lifted its position in Pfizer by 2.2% in the fourth quarter. Capital International Ltd. CA now owns 371,336 shares of the biopharmaceutical company’s stock worth $10,691,000 after buying an additional 7,991 shares during the last quarter. Capital International Sarl raised its stake in shares of Pfizer by 9.3% during the fourth quarter. Capital International Sarl now owns 438,138 shares of the biopharmaceutical company’s stock valued at $12,614,000 after acquiring an additional 37,233 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Pfizer by 283.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 705,479 shares of the biopharmaceutical company’s stock valued at $20,311,000 after purchasing an additional 521,677 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in shares of Pfizer by 1.4% during the 4th quarter. Crossmark Global Holdings Inc. now owns 78,863 shares of the biopharmaceutical company’s stock worth $2,271,000 after purchasing an additional 1,107 shares during the last quarter. Finally, Morningstar Investment Management LLC lifted its holdings in shares of Pfizer by 4.8% during the 4th quarter. Morningstar Investment Management LLC now owns 37,016 shares of the biopharmaceutical company’s stock valued at $1,066,000 after purchasing an additional 1,710 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.